AZ in £Billion Takeover deal for in vivo delivery platform17 Mar 2025 07:18
AstraZeneca is paying £1Billion for a small in vivo delivery platform, it has been announced today. AZ is buying EsoBiotec for a total consideration of up to $1bn, with an initial payment of $425m on deal closing, and up to $575m in contingent consideration based on development and regulatory milestones. N4P's value has just gone up today based on this deal. See relevant details below.... Good luck, Brighty
* AstraZeneca to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer many more patients access to transformative cell therapy treatments delivered in just minutes rather than the current process which takes weeks.
* ENaBL uses highly targeted lentiviruses to deliver genetic instructions to specific immune cells, such as T cells, which programme them to recognise and destroy tumour cells for cancer treatment or autoreactive cells for potential use in immune-mediated diseases. This approach enables cell therapies to be administered through a simple IV injection and without the need for immune cell depletion.
* Traditional cell therapies require cells to be removed from a patient, genetically modified outside the body, and then readministered to the patient as a medicine after immune cell depletion, typically taking weeks. By engineering immune cells directly within the patients body, the EsoBiotec in vivo approach has the potential to address many of the barriers associated with traditional cell therapies, reducing complexities and manufacturing timelines, thereby increasing access for patients.
Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: We are excited about the acquisition of EsoBiotec and the opportunity to rapidly advance their promising in vivo platform. We believe it has the potential to transform cell therapy and will enable us to scale these innovative treatments so that many more patients around the world can access them. EsoBiotec will accelerate and expand the impact of our recent investments and marks a major step forward in realising our ambition to harness the full potential of cell therapy.
About EsoBiotec
EsoBiotec is a leading in vivo cell therapy company with the mission to make these innovative treatments more accessible, effective and affordable. By engineering immune cells directly within the patients body, EsoBiotec is eliminating the barriers of traditional cell therapies and unlocking new possibilities for oncology and immune-mediated diseases.
EsoBiotecs proprietary ENaBL platform redefines adoptive cell therapy, enabling single IV, off-the-shelf treatments that reduce costs, improve patient experience, eliminate the need for immune cell depletion and have the potential to improve efficacy and safety through advanced lentiviral vector technology.
Sign In
Follow the stocks
